Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

1263 results about "CD8" patented technology

CD8 (cluster of differentiation 8) is a transmembrane glycoprotein that serves as a co-receptor for the T cell receptor (TCR). Like the TCR, CD8 binds to a major histocompatibility complex (MHC) molecule, but is specific for the class I MHC protein. There are two isoforms of the protein, alpha and beta, each encoded by a different gene. In humans, both genes are located on chromosome 2 in position 2p12.

Humanized Anti-CD8 antibodies and uses thereof

The present disclosure provides humanized antibodies and antigen binding domains thereof that bind CD8α and other antibody formats comprising these antigen binding domains, their use as a targeting moiety on lipid nanoparticles (tLNP) to deliver a therapeutic payload (such as a nucleic acid molecule) or other types of payloads. The present disclosure further relates to pharmaceutical compositions comprising the humanized anti-CD8α antibodies and CD8-targeted tLNP encapsulating a payload.
Owner:CAPSTAN THERAPEUTICS INC +5

Brucella recombinant multivalent epitope vaccine

PendingCN119015404Aavoid decompositionprecise targetingBacterial antigen ingredientsAntibacterial agentsAnaphylaxisHuman brucellosis
The invention belongs to the technical field of biomedicine, and particularly discloses a Brucella recombinant multivalent epitope vaccine which comprises IgVCTLA-4, a connected CD8 < + > T cell epitope, a connected CD4 < + > T cell epitope, a connected linear B cell epitope and a connected conformation B cell epitope. The protein of the vaccine provided by the invention is stable, hydrophilic and soluble, does not have anaphylaxis, has good immunogenicity, is expected to activate an organism to generate an effective immune response against brucella infection, blocks infection between livestock and people, realizes effective prevention and control of human brucellosis, and has good application prospects. The method can be a powerful method for preventing the occurrence and development of brucellosis in the future.
Owner:FIRST AFFILIATED HOSPITAL OF XINJIANG MEDICAL UNIVERSITY

Pharmaceutical composition of paclitaxel dimer prodrug nanoparticles and traditional Chinese medicine compound and application of pharmaceutical composition

The invention relates to the technical field of biological medicine, and discloses a pharmaceutical composition of paclitaxel dimer prodrug nanoparticles and a traditional Chinese medicine compound and application of the pharmaceutical composition, and the pharmaceutical composition is composed of Qiyuansanlong prescription freeze-dried powder and paclitaxel dimer prodrug nanoparticles; wherein the paclitaxel dimer prodrug nanoparticles comprise one of NQO1 response type PTX dimer prodrug nanoparticles (PTX-Q-PTX NPs) or GSH (glutathione) response type PTX dimer prodrug nanoparticles (PTX-SeSe-PTXNPs), and the paclitaxel dimer prodrug nanoparticles comprise one of NQO1 response type PTX dimer prodrug nanoparticles (PTX-Q-PTX NPs) and GSH response type PTX dimer prodrug nanoparticles (PTX-SeSe-PTXNPs). According to the pharmaceutical composition disclosed by the invention, a traditional Chinese and western medicine synergistic treatment system is innovatively constructed, and the advantage of multi-dimensional synergistic interaction is shown. Firstly, an NQO1 / GSH double-response type intelligent release system is adopted, and a biomarker highly expressed by tumor tissue can be specifically responded to realize precise drug release, so that the PTX concentration in tumors is improved compared with that of a traditional dosage form, and meanwhile, the drug circulation time is prolonged. Secondly, the active ingredients in the Qiyuansanlong prescription freeze-dried powder can significantly down-regulate the PD-L1 expression level, synergistically enhance CD4 + T and CD8 + T cell infiltration, and form chemical-immune dual killing effects.
Owner:ANHUI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE

GPC3 derived antigen peptide vaccine, mRNA vaccine, saRNA vaccine and preparation method and application thereof

The invention discloses a GPC3 derived antigen peptide vaccine, an mRNA vaccine, a saRNA vaccine and a preparation method and application thereof. The amino acid sequence of the antigen peptide vaccine is one or any combination of more of amino acid sequences shown as SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6. According to the invention, an efficient pGPC3 model antigen peptide is screened on the basis of GPC protein, and pGPC3 mRNA and pGPC3 saRNA are designed according to a pGPC3 sequence example. The pGPC3saRNA (at) Lipi vaccine is prepared through a liposome technology, and due to the fact that limiting conditions such as nonapeptide and high-affinity binding with H-2I type molecules (H-2Kb) are adopted during pGPC3 polypeptide antigen screening, APC cells are facilitated to present antigens through an MHCI restrictive pathway, CD8 + T cells are activated, and GPC3 specific CTL is triggered to efficiently kill liver cancer cells. Finally, the pGPC3saRNA (at) Lipi vaccine can completely inhibit the growth of the liver cancer, the inhibition rate reaches 99.8%, and the liver cancer of 4 / 8 mice completely fades down. In addition, the method can be used for vaccine adjuvant and carrier research on a liver cancer subcutaneous transplantation tumor model.
Owner:HUNAN ACAD OF CHINESE MEDICINE +1

Bispecific cytokine fusion protein and application thereof

The invention discloses a bispecific cytokine fusion protein, which comprises an amino acid sequence of a type I cytokine and an amino acid sequence of a type II cytokine, and the amino acid sequence of the type I cytokine and the amino acid sequence of the type II cytokine are directly connected through a connecting peptide or are connected in series or in parallel through a fusion partner and the connecting peptide. Amino acid sequences of type I and type II cytokines are connected in series or in parallel to form the bispecific cytokine fusion protein, and the fusion protein can synergistically activate precursor depleted CD8 + T cells and terminal depleted CD8 + T cells, improve immunosuppression of a solid tumor complex microenvironment and release the potential of tumor immunotherapy. The invention further discloses nucleic acid, a carrier, a cell, a medicine or a medicine composition related to the bispecific cytokine fusion protein. The invention also discloses application of the bispecific cytokine fusion protein in preparation of drugs for treating cancers.
Owner:ZHEJIANG UNIV

Application of efonidipine in preparation of dendritic cell immunologic adjuvant

The invention relates to the technical field of cellular immunotherapy, in particular to application of efonidipine in preparation of a dendritic cell immunologic adjuvant. The invention provides an application of efonidipine in preparation of a dendritic cell immunologic adjuvant. It is found that efonidipine can promote maturation, migration and antigen presentation functions of DCs, and the homing ability of DCs and CD8 + T cell activation are remarkably improved. The activation aspect of efonidipine on DCs comprises improvement of expression of maturation indexes CD80, CD40 and CD86, expression of a migration index CCR7, activation of CD8 + T cells by antigen presentation and the like. The efonidipine used in the invention is a drug approved by FDA for clinical treatment of cardiovascular diseases, the application of the efonidipine in immunotherapy is found, new use of old drugs is realized, and the efonidipine has great economic value.
Owner:ACADEMY OF MILITARY MEDICAL SCIENCES

Nano photosensitizer modified by outer membrane vesicles of genetically engineered bacteria as well as preparation method and application of nano photosensitizer

The invention provides a nano photosensitizer modified by outer membrane vesicles of genetically engineered bacteria as well as a preparation method and application of the nano photosensitizer. The nano photosensitizer is a nano material with the particle size of 80-120 nm, and the nano photosensitizer modified by the genetically engineered bacterium outer membrane vesicle comprises dipalmitic acid phosphatidylcholine (DPPC), distearoyl phosphatidylcholine (DSPC), dioleoyl lecithin (DOPC), cholesterol, a small molecule dye and CD47nb-OMV membrane protein. The chemical structure of the small molecule dye is shown as a formula I or a formula II. The nano photosensitizer OBDlp modified by outer membrane vesicles of genetically engineered bacteria serves as a novel nano photosensitizer, tumor targeting PTT is mediated through NIR II FL / PA imaging, tumor immunogenicity is improved, antigen presenting cells are activated, and infiltration and functionalization of CD8 + T cells are caused. And OBDlp and laser are combined to induce release of a large amount of DAMPs and trigger ICD to promote maturation of cDC1s. Meanwhile, a CD47 nano antibody carried by the nano photosensitizer induces polarization of M1 phenotype macrophages by blocking a CD47-SIRP alpha signal transduction axis, and an immunosuppression tumor microenvironment is reversed.
Owner:GUANGDONG YUNZHAO MEDICAL TECH CO LTD

New application of moss phenol glucoside

The invention belongs to the technical field of medicines, and particularly discloses application of moss phenol glucoside in preparation of medicines for preventing and / or treating tumors. According to the method, activated CD8 + T cells, MC38-OVA cells and traditional Chinese medicine monomeric compounds are co-cultured, the traditional Chinese medicine monomeric compounds capable of effectively promoting the anti-tumor activity of the CD8 + T cells are selected by utilizing a high-content screening technology, and finally, the experiment is carried out by taking the moss phenol glucoside as a research object. In-vitro experiment results show that the moss phenol glucoside can significantly promote T cell activation, promote release of cell factors such as IFN-gamma and TNF-alpha, and enhance the killing effect of T cells on tumors. A mouse in-vivo tumor-bearing experiment result shows that the moss phenol glucoside can promote the anti-tumor activity of T cells so as to inhibit tumor growth, has no obvious toxic or side effect, can be used for preparing the medicine for preventing and / or treating tumors, and has a potential clinical application prospect and a relatively high economic value.
Owner:ZHENGZHOU UNIV

Application of CD4+CD8 + double-positive T cell in improvement of poor immune reconstruction of HIV infected patient

The invention discloses an application of CD4 + CD8 + double-positive T cells in improvement of poor immune reconstitution of HIV (human immunodeficiency virus) infected patients, and relates to the technical field of biological pharmacy, in particular to the application of preparation of the CD4 + CD8 + double-positive T cells in the poor immune reconstitution of the HIV infected patients. The number of peripheral blood CD4 + T cells of HIV infected patients is increased, the immune system of the patients is improved, and the probability of possible opportunity infection and other related diseases of the patients is reduced, so that the morbidity and mortality of the patients are reduced.
Owner:FIRST AFFILIATED HOSPITAL OF KUNMING MEDICAL UNIV

Immune microenvironment characteristic-based hepatocellular carcinoma treatment effect evaluation method and system

The method and system for evaluating the curative effect of hepatocellular carcinoma based on immune microenvironment characteristics are high in accuracy and reliability of evaluating the curative effect of hepatocellular carcinoma. The method comprises the following steps: (1) preparing a sample; (2) carrying out multiple immunohistochemical staining; (3) image acquisition and analysis; (4) analyzing spatial distribution characteristics; (5) multiplying the input image voxel signal numerical value by the weight vector of the convolution kernel, transmitting the multilayer convolution kernel, and finally obtaining a calculation result output by each network; and (6) establishing a prediction model: based on the spatial distribution characteristics and clinical characteristics of immune cells, constructing the prediction model by using the positive rate of CD8 + PD-L1 + and CD103 + CD8 + cells in the total area and the number of CD103 + cells within 30 microns around tumor cells so as to predict the immunotherapy curative effect of the HCC patient.
Owner:NANJING DRUM TOWER HOSPITAL

Above pox virus antigen epitope peptide and application thereof

The invention belongs to the technical field of immunotherapy, and particularly relates to a monkey pox virus antigen epitope peptide and application thereof. The invention aims to solve the technical problem that at present, a T cell antigen epitope peptide for universal vaccines of monkey pox viruses is not developed in the field of monkey pox viruses. According to the technical scheme of the invention, the amino acid sequence of the monkey pox virus antigen epitope peptide is shown as SEQ ID No.2. The antigen epitope peptide provided by the invention has very strong immunogenicity, and can induce antigen-specific CD8 + T cells; the antibody can be directly loaded to antigen presenting cells, can activate T cells and effectively induce T cell immunity, and can be used for research and development and preparation of universal vaccines for monkey pox viruses, research and development of drugs and clinical treatment.
Owner:THE FIRST AFFILIATED HOSPITAL OF JINAN UNIV +1

Method for constructing differential diagnosis model of lupus nephritis and membranous nephropathy

The invention discloses a method for constructing a differential diagnosis model for lupus nephritis and membranous nephropathy, and belongs to the technical field of intelligent medical treatment. The modeling method comprises the following steps: S1, respectively collecting flow cytometry detection data of lupus nephritis patients and healthy control personnel; s2, performing data cleaning and conversion on the flow cytometry detection data, and converting non-numerical features into digits; carrying out implication on the missing value by adopting a k nearest neighbor algorithm from an implication packet; s3, random sampling is carried out on the cleaned and converted data set, and samples are divided into a training set and a verification set according to the proportion of 7: 3; s4, dividing a training subset and a test set from the training set, and iteratively selecting the types of cells incorporated into the constructed model as pDC, CD4T, effector CD4T, Th2, CD8T, CD38 + HLA-DR + CD8T, and CD38 + PD-1 + CD8T by adopting an RFE method, wherein the types of the cells incorporated into the constructed model are pDC, CD4T, effector CD4T, Th2, CD8T, CD38 + HLA-DR + CD8T and CD38 + PD-1 + CD8T; and S5, performing a classification task by adopting TabPFNClassifier, performing training from features selected from the training data set, then evaluating the performance of the model, performing model training by utilizing detection data, and performing evaluation to construct a lupus nephritis prediction model with high accuracy.
Owner:BEIJING HOSPITAL

Application of GATA3 inhibitor and PD1 inhibitor in preparation of medicine for treating breast cancer

The invention relates to application of a GATA3 inhibitor and a PD1 inhibitor in preparation of a medicine for treating breast cancer, and belongs to the technical field of biological medicine. The invention discloses application of a GATA3 inhibitor and a PD1 inhibitor in preparation of a medicine for treating breast cancer. The GATA3 regulates the transcription regulation of IFNbeta by inhibiting the enhancer activity of IFNB1, down-regulates an I-type interferon signal channel, inhibits the secretion of an MHC-I antigen presentation channel and a chemotactic factor CCL5 of breast cancer cells, reduces immune recognition, and achieves the purpose of immune escape. The immunotherapy for inhibiting GATA3 combined with the PD1 inhibitor to treat breast cancer effectively treats breast cancer mice, improves the IFN beta level in the mice, promotes the MHC-I antigen presentation pathway of the mice, improves the CCL5 level in the mice, and improves the CD8 + T cell level in a tumor immune microenvironment, thereby reducing tumor occurrence and inhibiting tumor growth.
Owner:THE SEVENTH AFFILIATED HOSPITAL SUN YAT SEN UNIV SHENZHEN

Anti-pancreatic cancer dendritic cell vaccine as well as preparation method and application thereof

The invention provides an anti-pancreatic cancer dendritic cell vaccine as well as a preparation method and application thereof, and belongs to the technical field of tumor vaccines. The anti-pancreatic cancer dendritic cell vaccine comprises dendritic cells loaded with at least one of the following antigens: induced pluripotent stem cell lysate and induced pluripotent stem cell exosome. The vaccine can obviously stimulate proliferation of T cells and can specifically induce proliferation of CD8 + T lymphocytes, so that the vaccine has obvious killing activity on three pancreatic cancer tumor cell lines. Meanwhile, the vaccine shows a good anti-pancreatic cancer effect in preventive inoculation in a human immune reconstruction mouse pancreatic cancer tumor model.
Owner:SHANDONG GOLDEN BRICK BIOTECHNOLOGY CO LTD

Traditional Chinese medicine composition for treating triple negative breast cancer and application thereof

The invention belongs to the field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating triple negative breast cancer and application thereof. The traditional Chinese medicine composition is prepared from the following main active ingredients in parts by mass: 20 to 40 parts of radix astragali seu hedysari, 10 to 20 parts of rhizoma curcumae, 10 to 20 parts of herba hedyotidis diffusae, 5 to 15 parts of fructus aurantii immaturus, 5 to 15 parts of radix bupleuri, 5 to 15 parts of radix paeoniae alba and 5 to 15 parts of liquorice root. Animal experiments show that the traditional Chinese medicine composition can significantly inhibit tumor growth and pulmonary metastasis of triple-negative breast cancer tumor-bearing mice, increase the proportion of CD8 + T lymphocytes in blood, reduce the proportion of MDSCs, significantly down-regulate the expression of pro-inflammatory cytokines such as IL-6, IL-1alpha, CXCL1 and GM-CSF in serum, and cooperate with PD-L1 immunotherapy to achieve a synergistic effect. And the whole blood and liver and kidney function indexes are in a normal range. Therefore, the traditional Chinese medicine composition disclosed by the invention can be used for effectively inhibiting the tumor growth and pulmonary metastasis of the triple negative breast cancer, remodeling the immune state of an organism and reducing the release of proinflammatory factors, and is safe, reliable, free of obvious liver and kidney toxicity and blood toxicity and small in side effect.
Owner:GUANGDONG HOSPITAL OF TRADITIONAL CHINESE MEDICINE

Application of lactyltransferase inhibitor in pancreatic cancer and immunotherapy thereof

The invention relates to the technical field of cancer treatment, and provides application of a lactyltransferase inhibitor in pancreatic cancer and immunotherapy thereof. According to the present invention, the histone lactosyltransferase inhibitor and the anti-programmed death receptor-1 antibody are combined to form the composition for pancreatic cancer and immunotherapy thereof, such that the recognition and the removal of the immune system on the cancer cells can be enhanced, the growth of the pancreatic cancer tumor can be effectively inhibited, and the survival time of the pancreatic cancer patient can be prolonged. The histone lactosyltransferase inhibitor reduces the infiltration level of tumor-associated neutrophil, increases the infiltration level of CD8 positive T cells, reverses the composition of a pancreatic cancer inhibitory immune microenvironment, and generates a synergistic anti-tumor effect with an anti-programmed death receptor-1 antibody. The traditional Chinese medicine composition is suitable for early-stage, middle-stage and late-stage treatment of pancreatic cancer, improves the survival rate and the treatment effect of pancreatic cancer patients, remarkably reduces the side effects of treatment and improves the living quality of the pancreatic cancer patients.
Owner:南昌大学第一附属医院

Genetically modified rodents and rodent cells, and uses thereof

PCT designated stage expiredWO2025032222A1Immunoglobulin superfamilyDepsipeptidesHuman sequenceCD8
Transgenic rodents and rodent cells that express components of the human immune system, and their uses in generating human T cell receptors (TCRs). A genetically modified rodent comprising a TCR alpha gene locus comprising unrearranged human TCR alpha variable gene segments and a human TCR alpha constant region, and a TCR beta gene locus comprising unrearranged human TCR beta variable gene segments and a human TCR beta constant region. Use of hTCR transgenic rodents to generate antigen-specific CD8+ T cell responses for the discovery of fully human TCR sequences with therapeutic potential.
Owner:CAMBRIDGE ENTERPRISE LTD

Combinations of nanoparticle-loaded immune agonists and ras targeted therapies for treatment of cancer

PCT designated stage expiredWO2024238486A2Organic active ingredientsAntineoplastic agentsStage tumorCD8
Described herein is the combination of STING / TLR4 agonist nanoparticles (NPs) and a combination of a MEK inhibitor (e.g., trametinib) and CDK4 / 6 inhibitor (e.g., palbociclib) treatment. This combination synergizes to (a) lead to enhanced NP uptake in multiple cell types in the TME, (b) increased antigen presentation on tumors cells as well as APCs, and (c) CD8+ T cell mediated long-term tumor control that is interferon signaling dependent. Also provided are methods to treat cancer, e.g., KRAS mutant cancers, e.g., KRAS mutant PDAC or lung cancer.
Owner:UNIV OF MASSACHUSETTS

Application of ackermann muciniphile or external vesicles thereof in preparation of drugs for treating schistosomiasis

The invention belongs to the technical field of biological medicines, and relates to application of Ackermann muciniphile or its external vesicles in preparation of a drug for treating schistosomiasis. The anti-infection immunity of a host is enhanced by adjusting intestinal flora balance (recovering diversity and composition) and improving immune response (adjusting macrophage, CD8 + T cell recruitment and Th1 / Th2 balance); meanwhile, the intestinal barrier function is improved, and pathogen invasion and inflammation are reduced; hepatic granuloma and hepatic fibrosis caused by schistosome infection are obviously relieved, and the liver function is improved; the key effect of the MIF gene in immunoregulation is disclosed, and a new direction is provided for schistosomiasis immunotherapy. Besides, the probiotics are high in treatment safety and free of obvious side effects, can be combined with chemotherapy to enhance the curative effect and reduce the side effects and drug resistance of chemical drugs, provides a lasting and comprehensive adjuvant therapy scheme for the schistosomiasis, and has important clinical application potential.
Owner:HUBEI UNIV OF MEDICINE

TCR nano-vesicle antibody with functions of T cell redirection and immunosuppression reversal as well as preparation method and application of TCR nano-vesicle antibody

The invention relates to the technical field of nano-drug presentation systems, in particular to a TCR (T cell receptor) nano-vesicle antibody with both T cell redirection and immunosuppression reversal as well as a preparation method and application of the TCR nano-vesicle antibody. The TCR nano-vesicle antibody comprises a vesicle formed by a liposome and a cell membrane; tCR protein, a PD-1 antibody and a CD3 antibody are loaded on the vesicles. The nano vesicle antibody has the functions of T cell redirection and immunosuppression reversion; the difficulty of low stability of the soluble TCR is overcome; the polypeptide can be rapidly enriched in tumor tissues through tumor specificity TCR, and CD8 + T cells infiltrated by tumors are directly activated through an anti-CD3 antibody; depletion of T cells can be reversed through the PD-1 antibody on the surface, and the effector function of tumor infiltration CD8 + T cells is improved. The technical scheme can solve the technical problems that the TCR stability is not ideal and the immunosuppression state of the tumor microenvironment is difficult to overcome, and has ideal application and popularization prospects.
Owner:CHONGQING MATERNAL & CHILD HEALTH HOSPITAL (CHONGQING OBSTETRICS & GYNECOLOGY HOSPITAL CHONGQING INST OF GENETICS & REPRODUCTION)

Method for performing sarcoma high-frequency neoantigen function verification based on tumor organoids

PendingCN119410741ACompound screeningApoptosis detectionAntigen stimulationCD8
The invention discloses a method for performing sarcoma high-frequency neoantigen function verification based on tumor organoids, and the method for performing sarcoma high-frequency neoantigen function verification based on tumor organoids comprises the following steps: after separating PBMC, enriching CD8 + T cells, and stimulating the CD8 + T cells by using DC loaded with candidate neoantigen polypeptide to obtain neoantigen specific CTL; new antigen-specific CTL is tested through the kit, secretion of IFN-gamma is detected, and antigen-specific CTL with positive reaction is screened out; the method comprises the following steps: selecting a candidate new antigen capable of specifically stimulating CTL to generate an IFN-gamma positive reaction according to an experiment result of secreting IFN-gamma by the CTL, establishing a tumor organoid-CTL cell co-culture system, setting PBMC primary T cells of a patient which are not stimulated by DC loaded with the candidate new antigen as a control group, and measuring organoid light microscope radiography and tumor cell death conditions. The function of the sarcoma high-frequency neoantigen is evaluated based on tumor organs.
Owner:SHANGHAI TONGREN HOSPITAL +1

Combined traditional Chinese medicine composition for treating tumors by improving tumor immune microenvironment and application of combined traditional Chinese medicine composition

The invention relates to a combined traditional Chinese medicine composition for treating tumors by improving a tumor immune microenvironment and application thereof. The combined traditional Chinese medicine composition comprises rhein and hesperidin. Rheinic acid and hesperidin have stronger antitumor activity than single components in combined application, and the combined pharmaceutical composition can significantly inhibit the growth of cancer-related fibroblasts, reduce CCL2 secreted by cancer-related adipocytes and increase infiltration of CD8 + T cells at tumor sites, so that the growth of tumors is significantly inhibited, and the antitumor effect is improved. And a new method and thought are provided for combined treatment of cancers.
Owner:ZHEJIANG CHINESE MEDICAL UNIVERSITY

Establishment and application of HBV (Hepatitis B Virus) specific depletion type CD8 + T cell mouse model

The invention discloses construction and application of an HBV (Hepatitis B Virus) specific depletion type CD8 < + > T cell mouse model. The preparation method comprises the following steps: firstly, immunizing a CD45.1 type C57 mouse by adopting HBsAg and HBcAg antigen peptides of HBV so as to obtain a mouse with HBV specific immunization; the method comprises the following steps: carrying out X-ray marrow cleaning irradiation on a CD45.2 type C57 mouse of which the liver specifically expresses HBV transgene; the method comprises the following steps: collecting the bone marrow of a CD45.1 type mouse subjected to HBV specific immunization, and performing orbital vein transplantation on the CD45.2 type mouse subjected to marrow removal irradiation; after transplantation, flow cytometry is adopted to detect HBV specific CD8 + T cells and depletion-related phenotypes, and establishment of the HBV specific depletion-type T cell mouse model is confirmed. The mouse model has high-level HBV specific CD8 + T cells, is remarkable in depletion phenotype, and can be applied to research on a formation mechanism of hepatitis B T cell depletion and related diagnosis and treatment new targets and new strategies.
Owner:THE FIRST AFFILIATED HOSPITAL ZHEJIANG UNIV COLLEGE OF MEDICINE

Method for inducing T cell immune memory differentiation in vitro and application

The invention discloses a method for in-vitro induction of T cell immune memory differentiation and application, CD8 + T memory differentiation can be enhanced by verifying in-vitro itaconic acid and derivative supplement thereof, and then anti-tumor and anti-infection immune response is enhanced after in-vivo feedback. The invention can be used in malignant tumors and infectious diseases to enhance the curative effect of T cell adoptive therapy.
Owner:XIEHE HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI & TECH UNIV

Methods for producing genetically engineered cell compositions and related compositions

Provided herein are methods and compositions for generating engineered cells, such as cells expressing a recombinant receptor, including methods involving stimulation and / or engineering of an input composition having a defined ratio of naïve-like CD4+ T cells to naïve-like CD8+ T cells. In particular, the methods can be used to engineer T cells with genetically engineered receptors, such as genetically engineered antigen receptors such as engineered (recombinant) TCRs and chimeric antigen receptors (CARs), or other recombinant chimeric receptors. Features of the methods include producing a more consistent and / or predictable T cell product and / or a product with lower toxicity compared with other methods.
Owner:JUNO THERAPEUTICS INC

Engineered vesicle for targeted editing of T cells as well as preparation method and application of engineered vesicle

The invention belongs to the technical field of gene drug delivery, and particularly relates to an engineered vesicle for targeted editing of T cells as well as a preparation method and application of the engineered vesicle. T cells with depletion potential are highly expressed by extracellular vesicles in a targeted PD-1, and a CRIPSR gene editing system is delivered to edit a DUSP2 gene, so that the depleted T cells obtain dry sample characteristics again and are further stimulated to become killer T cells, and the killing effect of tumor cells is enhanced; the engineering vesicle is utilized, namely, transmembrane protein LAMP2 is utilized to anchor PD-1 targeting peptide on the surface of the engineering vesicle, so that the engineering vesicle can specifically target PD-1 high-expression T cells with depletion potential, a CRISPR / Cas9 system is delivered, expression of DUSP2 is reduced, CD8 + T cells are effectively promoted to obtain dry characteristics, and depletion phenotypes are reversed; meanwhile, CD4 + T cells are effectively promoted to play an auxiliary function, interferon (IFN-gamma) and other effector factors are secreted, the immune microenvironment is adjusted, and the tumor cell killing effect is synergistically enhanced.
Owner:JIANGSU SECOND NORMAL UNIVERSITY

Genetically modified mice comprising humanized cellular immune system components with improved diversity of TCRB repertoire

Disclosed herein are non-human animals (e.g., rodents, e.g., mice or rats) genetically engineered to express a human or humanized T cell receptor (TCR) from a human or humanized TCR locus comprising a non-human TCR non-coding sequence, and optionally a humanized T cell co-receptor (e.g., humanized CD4 and / or CD8 (e.g., CD8α and / or CD8β)), and / or a human or humanized major histocompatibility complex that binds the humanized T cell co-receptor (e.g., human or humanized MHC II (e.g., MHC II α and / or MHC II β chains) and / or MHC I (e.g., MHC Iα) respectively, and optionally human or humanized β2 microglobulin). Also provided are embryos, tissues, and cells expressing the same. Methods for making the genetically engineered animals are also provided. Methods for using the genetically engineered animals for developing human therapeutics are also provided.
Owner:REGENERON PHARMACEUTICALS INC

Application of lactobacillus fermentum in preparation of antitumor drugs

The invention relates to the field of biological medicine, in particular to application of fermented lactobacillus mucus in preparation of immune antitumor drugs. A strain of fermented lactobacillus mucus capable of effectively treating tumors is screened and can activate the immune system of the strain, increase the proportion of CD8 + T lymphocytes in spleen tissues, increase the infiltration proportion of leukocytes in tumors and the proportion of CD4 + and CD8 + T lymphocytes in infiltrated immune cells, change the tumor microenvironment and improve the tumor immunity. Therefore, tumor cells are effectively killed, and the effect of tumor immunotherapy is achieved.
Owner:CHINA PHARM UNIV